Am Fam Physician. 2007 Oct 1;76(7):1014-1016.
What are the effects of drug treatments for primary hyperthyroidism?
LIKELY TO BE BENEFICIAL
Antithyroid Drugs (Carbimazole, Propyl-thiouracil, and Thiamazole)
We found no randomized controlled trials (RCTs) comparing antithyroid drug treatment with placebo in persons with hyperthyroidism, although there is consensus that treatment is beneficial. We found no RCTs comparing antithyroid drugs (carbimazole, propylthiouracil, or thiamazole) with each other. One systematic review found that fewer persons relapsed with 18 months of higher-dose antithyroid drug treatments than with six months; however, it found no significant difference for more than 18 months compared with 12 to 18 months of lower-dose treatment. One systematic review found that a similar number of persons relapsed to hyperthyroidism with antithyroid drugs alone (titration) and antithyroid drugs plus thyroxine (block replace). One RCT found a similar proportion of persons who relapsed and who became euthyroid between high-and low-dose thiamazole. However, it found that adverse effects were lower with titration regimens. There have been concerns about bone marrow suppression, neutropenia, and agranulocytosis with antithyroid drugs. The doses of antithyroid drugs reported in the studies are higher than are generally used in practice. (Based on consensus because RCTs would be considered unethical.)
Radioactive Iodine (in Persons Without Ophthalmopathy; May Increase Ophthal-mopathy in Persons with Graves' Disease)
We found no RCTs comparing radioiodine with placebo in persons with hyperthyroid-ism, although there is consensus that treatment is beneficial. Cohort studies found that radioiodine can increase some thyroid and extrathyroid cancers but not overall incidence of cancer. RCTs found that radioio-dine can worsen ophthalmopathy in persons with Graves' disease compared with other treatments. (Based on consensus because RCTs would be considered unethical.)
UNLIKELY TO BE BENEFICIAL
Adding Thyroxine to Antithyroid Drugs (Carbimazole, Propylthiouracil, and Thiamazole)
One systematic review found that a similar number of persons relapsed to hyperthyroid-ism between antithyroid drugs plus thyroxine (block replace) and antithyroid drugs alone (titration). However, it found that adverse effects were higher with block replace regimens. Another systematic review found no significant difference in relapse between thyroxine and no treatment after antithyroid treatment.
What are the effects of surgical treatments for primary hyperthyroidism?
LIKELY TO BE BENEFICIAL
We found no RCTs comparing surgery with placebo in persons with hyperthyroidism, although there is consensus that treatment is beneficial. One systematic review and subsequent RCT found that total thyroidectomy decreased hyperthyroidism and increased euthyroidism and hypothyroidism compared with subtotal thyroidectomy. However, another subsequent RCT found no significant difference among bilateral subtotal, unilateral total, and contralateral subtotal, and total thyroidectomy in improvement in Graves' ophthalmopathy. The systematic review and RCTs did not find sufficient evidence that adverse effects were worse with total or subtotal thyroidectomy. (Based on consensus because RCTs would be considered unethical.)
What are the effects of treatments for subclinical hyperthyroidism?
LIKELY TO BE BENEFICIAL
Any Antithyroid Treatment
One controlled clinical trial found that thyroid-stimulating hormone (TSH; also known as thyrotropin) and bone mineral density were higher in women given radioiodine compared with no treatment in women with no compression symptoms from a nodular goiter.
Hyperthyroidism is characterized by high levels of serumthyroxine (T4), high levels of serum triiodothyronine (T3), or both, and low levels of TSH. Subclinical hyperthyroidism is characterized by decreased levels of TSH (less than 0.1 mIU per L) but with levels of T4 and T3 within the normal range (total T4: 5 to 11 mcg per dL [64 to 142 nmol per L]; total T3: 65.19 to 162.97 ng per dL [1.0 to 2.5 nmol per L], depending on assay type).1 The terms hyperthyroidism and thyrotoxicosis are often used synonymously; however, they refer to slightly different conditions. Hyperthyroidism refers to overactivity of the thyroid gland leading to excessive production of thyroid hormones. Thyrotoxicosis refers to the clinical effects of unbound thyroid hormones, whether or not the thyroid gland is the primary source.2
Secondary hyperthyroidism owing to pituitary adenomas, thyroiditis, iodine-induced hyperthyroiditis, and treatment of children and pregnant or lactating women are not covered in this review. Hyperthyroidism can be caused by Graves' disease (diffusely enlarged thyroid gland on palpation, ophthalmopathy, and dermopathy), toxic multinodular goiter (thyrotoxicosis and increased radioiodine uptake with multinodular goiter on palpation), or toxic adenoma (benign hyperfunctioning thyroid neoplasm presenting as a solitary thyroid nodule).1 We have not included treatment of Graves' ophthalmopathy in this review, although we do report on worsening of Graves' ophthalmopathy with radioiodine. We also have not included euthyroid sick syndrome (a condition occurring in persons with, for example, pneumonia, acute myocardial infarction, cancer, and depression; it is characterized by low levels of TSH and T3).
The diagnosis of hyperthyroidism is established by a raised serum total or freeT4 or T3 hormone levels, reduced TSH level, and high radioiodine uptake in the thyroid gland with features of thyrotoxicosis. The usual symptoms are irritability, heat intolerance and excessive sweating, palpitations, weight loss with increased appetite, increased bowel frequency, and oligomenorrhea. Persons with hyperthyroidism also often have tachycardia, fine tremors, warm and moist skin, muscle weakness, and eyelid retraction or lag.1
Incidence and Prevalence
Hyperthyroidism is more common in women than in men. One study (2,779 persons in the United Kingdom; median age 58 years; 20 years' follow-up) found an incidence of clinical hyperthyroidism of 0.8 per 1,000 women a year (95% confidence interval [CI], 0.5 to 1.4 per 1,000 women a year).3 The study reported that the incidence was negligible in men.
In areas with low iodine intake, the incidence of hyperthyroidism is higher than in areas with high iodine intake because suboptimal iodine intake induces nodular goiter, and by the time the nodules become autonomic, hyperthyroidism develops.4 In Denmark, with moderate iodine insufficiency, the overall incidence of hyperthyroidism (defined as low levels of TSH) is 9.7 percent compared with 1.0 percent in Iceland with high iodine intake. The prevalence in the Danish study was 38.7 per 100,000 women a year and two per 100,000 men a year.5
Smoking is a risk factor, with an increased risk of Graves' disease (odds ratio [OR] = 2.5; 95% CI, 1.8 to 3.5) and toxic nodular goiter (OR = 1.7; 95% CI, 1.1 to 2.5).6 In areas with high iodine intake, the major cause is Graves' disease, whereas nodular goiter is the major cause in areas with low iodine intake.5 A correlation between diabetes mellitus and thyroid dysfunction has been described. In a Scottish population with diabetes, the overall prevalence of thyroid disease was 13 percent; the prevalence was highest in women with type 1 diabetes (31 percent). As a result of screening, new thyroid disease was diagnosed in 7 percent of persons with diabetes (hyperthyroidism in 1 percent).7
Clinical hyperthyroidism can be complicated by severe cardiovascular or neuropsychiatry manifestations requiring hospital admission or urgent treatment.
One population-based 10-year cohort study of 1,191 persons at least 60 years of age found a higher mortality among persons who had a low initial TSH level. The excess in mortality was attributable to cardiovascular diseases. However, the persons in this study who had a low TSH level may have had a higher prevalence of other illnesses, and adjustment was done only for age and sex, not for comorbidity.8 We found another population-based study evaluating 3,888 persons with hyperthyroidism. No increase was found in all-cause mortality or serious vascular events in persons whose hyperthyroidism was treated and stabilized, but an increased risk of dysrhythmias was found in persons treated for hyperthyroidism compared with the standard population (standardized incidence ratio = 2.71; 95% CI, 1.63 to 4.24).9
ATRIAL FIBRILLATION IN PERSONS WITH OVERT HYPERTHYROIDISM
We found one cohort study evaluating the incidence of atrial fibrillation in persons older than 60 years with low serum TSH concentrations (0.1 mIU per L or less). It found that low serum TSH concentrations were associated with an increased risk of atrial fibrillation (diagnosed by electrocardiography) at 10 years (61 persons with low TSH and 1,576 persons with normal TSH; incidence of atrial fibrillation was 28 per 1,000 person-years with low TSH values versus 11 per 1,000 person-years with normal TSH values; 13 out of 61 [21 percent] persons with low TSH values versus 133 out of 1,576 [8 percent] persons with normal TSH values; relative risk [as calculated by Clinical Evidence] = 2.53; 95% CI, 1.52 to 4.20).10 A population-based study including 40,628 persons diagnosed with hyperthyroidism in Denmark from 1977 to 1999 found that 8.3 percent were diagnosed with atrial fibrillation or flutter within 30 days from the date of diagnosis of hyperthyroidism.11
QUALITY OF LIFE
The quality of life of persons with thyroid problems can be reduced in many ways if left untreated, and this can continue in the long term. In a long-term follow-up (179 persons, treated for 14 to 21 years before investigation), persons with Graves' disease had diminished vital and mental quality-of-life aspects even after years of treatment compared with a large Swedish reference population.12
FRACTURE RATE AND BONE MINERAL DENSITY
Hip and spine bone mineral density levels can decrease if hyperthyroidism is untreated.13 However, when treated, bone mineral density can increase to normal levels. The risk of hip fracture is also higher in persons with hyper-thyroidism. Progression from subclinical to overt hyperthyroidism occurs in persons with nodular goiter but not in persons found by screening without other signs of thyroid disease.14 A meta-analysis (search date 1996), based on data from screening studies, estimated that each year 1.5 percent of women and 1.0 percent of men who had a low TSH level and normal free T4 and T3 levels developed an elevated free T4 or T3 level.14 Ophthalmopathy is a complication of Graves' hyperthyroidism. Treatment can be problematic and usually involves topical corticosteroids and external radiation of the eye muscles.
THYROID VOLUME AND THE NODULARITY OF THE GLAND INFLUENCE THE CURE RATE OF HYPERTHYROIDISM
In a controlled study of 124 persons with newly diagnosed hyperthyroidism, remission rates were calculated after treatment with a combined antithyroid drug plus T4 for about two years. Persons with Graves' disease who did not have a goiter or had a small goiter had a significantly better outcome compared with persons with Graves' disease who had a medium- or large-sized goiter. Most persons with multinodular goiter had a relapse within the first year after stopping medication.15
editor's note In the United States, carbimazole is not available, thiamazole is called methimazole, and thyrotropin is only available in the injectable form.
search date: April 2006
Adapted with permission from Nygaard B. Hyperthyroidism. Clin Evid Handbook June 2007:190–2.
REFERENCESshow all references
1. Singhal T, Bal CS, Chandra P. Adjunctive antithyroid drugs in radioiodine therapy for hyperthyroidism (protocol). Cochrane Database Syst Rev. 2005;(3):CD005447....
2. Lee SL, Ananthakrishnan S. Hyperthyroidism. eMedicine. Accessed July 20, 2007, at: http://www.emedicine.com/MED/topic1109.htm.
3. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorder in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55–68.
4. Laurberg P, Pedersen KM, Vestergaard H, et al. High incidence of multinodular toxic goitre in elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area. J Intern Med. 1991;229:415–20.
5. Laurberg P, Bulow Pedersen I, Pedersen KM, et al. Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Thyroid. 1999;9:33–8.
6. Vestergaard P, Rejnmark L, Weeke J, et al. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid. 2002;12:69–75.
7. Perros P, McCrimmon RJ, Shaw G, et al. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med. 1995;12:622–7.
8. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861–5.
9. Flynn RW, McDonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006;91:2159–64.
10. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.
11. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study [Published correction appears in Arch Intern Med 2005;165:307]. Arch Intern Med. 2004;164:1675–8.
12. Abraham-Nordling M, Torring O, Hamberger B, et al. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15:1279–86.
13. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk—a meta-analysis. Thyroid. 2003;13:585–93.
14. Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update [Published correction appears in Ann Intern Med 1999;130:246]. Ann Intern Med. 1998;129:144–58.
15. Laurberg P, Buchholtz Hansen PE, Iversen E, et al. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh). 1986;111:39–43.
This is one in a series of chapters excerpted from the Clinical Evidence Handbook, published by the BMJ Publishing Group, London, U.K. The medical information contained herein is the most accurate available at the date of publication. More updated and comprehensive information on this topic may be available in future print editions of the Clinical Evidence Handbook, as well as online athttp://www.clinicalevidence.com (subscription required). Those who receive a complimentary print copy of the Clinical Evidence Handbook from United Health Foundation can gain complimentary online access by registering on the Web site using the ISBN number of their book.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 1, 2016
Access the latest issue of American Family Physician